Marine Bacteriophages and Their Applications

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Biotechnology Related to Drug Discovery or Production".

Deadline for manuscript submissions: closed (15 June 2024) | Viewed by 1166

Special Issue Editor


E-Mail Website
Guest Editor
School of Science, Technology and Engineering, University of the Sunshine Coast, Maroochydore, QLD 4558, Australia
Interests: microbial ecology and diversity; microbial systematics; biodiscovery; microbial biotechnology applied; environmental and industrial microbiology; marine microbiology; biological control; actinomycetology; bacteriophages
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bacteria are continually evolving into antibiotic-resistant strains due to their extraordinary ability to adapt to changes in their environment and displaying extraordinary combat strategies to survive despite continuously improved antibiotic mechanisms of actions. Alternative therapies are thus gaining importance, and one effective such therapy is “bacteriophage therapy”. However, in order to use them as potent therapeutic agents, a diverse range of phages have to be isolated. This can only be achieved by improving our understanding of the phage–host interactions in natural environments. One of these natural environments is the marine one—in particular, the marine sediments that support bacterial life are proven to contain a significant number of phages. 

I, therefore, invite contributions from scientists who are researching the development of bacteriophage therapy using marine origin phages to combat antibiotic-resistant bacteria or for other types of biotechnological applications. The Special Issue is intended to capture the advances and fill the gaps within the current literature to be able to contribute toward an improved understanding of marine bacteriophages and, in turn, their use in medicine and industry.

Dr. Ipek Kurtboke
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine bacteriophages
  • bacteriophage therapy
  • bacteriophage biological control
  • bacteriophage lysins
  • pathogenic bacteria of marine origin
  • host–phage interactions in the marine environments
  • bacteriophages in marine aquaculture and fisheries operations
  • seafood-associated bacteria and their phages

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 5614 KiB  
Article
Characterization and Genomic Analyses of dsDNA Vibriophage vB_VpaM_XM1, Representing a New Viral Family
by Zuyun Wei, Xuejing Li, Chunxiang Ai and Hongyue Dang
Mar. Drugs 2024, 22(9), 429; https://doi.org/10.3390/md22090429 - 21 Sep 2024
Viewed by 644
Abstract
A novel vibriophage vB_VpaM_XM1 (XM1) was described in the present study. Morphological analysis revealed that phage XM1 had Myovirus morphology, with an oblate icosahedral head and a long contractile tail. The genome size of XM1 is 46,056 bp, with a G + C [...] Read more.
A novel vibriophage vB_VpaM_XM1 (XM1) was described in the present study. Morphological analysis revealed that phage XM1 had Myovirus morphology, with an oblate icosahedral head and a long contractile tail. The genome size of XM1 is 46,056 bp, with a G + C content of 42.51%, encoding 69 open reading frames (ORFs). Moreover, XM1 showed a narrow host range, only lysing Vibrio xuii LMG 21346 (T) JL2919, Vibrio parahaemolyticus 1.1997, and V. parahaemolyticus MCCC 1H00029 among the tested bacteria. One-step growth curves showed that XM1 has a 20-min latent period and a burst size of 398 plaque-forming units (PFU)/cell. In addition, XM1 exhibited broad pH, thermal, and salinity stability, as well as strong lytic activity, even at a multiplicity of infection (MOI) of 0.001. Multiple genome comparisons and phylogenetic analyses showed that phage XM1 is grouped in a clade with three other phages, including Vibrio phages Rostov 7, X29, and phi 2, and is distinct from all known viral families that have ratified by the standard genomic analysis of the International Committee on Taxonomy of Viruses (ICTV). Therefore, the above four phages might represent a new viral family, tentatively named Weiviridae. The broad physiological adaptability of phage XM1 and its high lytic activity and host specificity indicated that this novel phage is a good candidate for being used as a therapeutic bioagent against infections caused by certain V. parahaemolyticus strains. Full article
(This article belongs to the Special Issue Marine Bacteriophages and Their Applications)
Show Figures

Figure 1

Back to TopTop